Seroquel XR approved as add-on treatment in Major Depressive Disorder
Date: 04 May 2012

Seroquel XR (quetiapine fumarate) has been approved by European and Cypriot regulatory authorities as add-on treatment of major depressive episodes in patients with Major Depressive Disorder (MDD) who have had sub-optimal response to antidepressant monotherapy. Seroquel is a drug researched, developed and commercialised by AstraZeneca UK.
For more information about Seroquel XR please click here.